Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Shares Issued (2018 - 2025)

Dianthus Therapeutics has reported Shares Issued over the past 7 years, most recently at $272.3 million for Q3 2025.

  • Quarterly results put Shares Issued at $272.3 million for Q3 2025, up 85718.55% from a year ago — trailing twelve months through Sep 2025 was $311.5 million (changed N/A YoY), and the annual figure for FY2024 was $39.2 million, up 783900.0%.
  • Shares Issued for Q3 2025 was $272.3 million at Dianthus Therapeutics, up from $1000.0 in the prior quarter.
  • Over the last five years, Shares Issued for DNTH hit a ceiling of $272.3 million in Q3 2025 and a floor of -$1.1 million in Q2 2022.
  • Median Shares Issued over the past 4 years was $3000.0 (2023), compared with a mean of $38.8 million.
  • Biggest five-year swings in Shares Issued: crashed 6460.0% in 2024 and later skyrocketed 85718.55% in 2025.
  • Dianthus Therapeutics' Shares Issued stood at -$49000.0 in 2022, then skyrocketed by 110.2% to $5000.0 in 2023, then surged by 783900.0% to $39.2 million in 2024, then soared by 594.56% to $272.3 million in 2025.
  • The last three reported values for Shares Issued were $272.3 million (Q3 2025), $1000.0 (Q1 2025), and $39.2 million (Q4 2024) per Business Quant data.